Suppr超能文献

高血压合并糖尿病患者的管理策略:为何联合治疗至关重要。

Management strategies for patients with hypertension and diabetes: why combination therapy is critical.

作者信息

Giunti Sara, Cooper Mark

机构信息

Danielle Alberti Memorial Centre for Diabetic Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Australia.

出版信息

J Clin Hypertens (Greenwich). 2006 Feb;8(2):108-13. doi: 10.1111/j.1524-6175.2005.04508.x.

Abstract

Hypertension is commonly associated and acts synergistically with diabetes in increasing the risk of macrovascular and microvascular diabetic complications. Large-scale clinical trials have demonstrated that this risk is significantly reduced by intensive antihypertensive treatment, and accordingly, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guideline has further lowered the blood pressure goals for diabetic subjects to <130/80 mm Hg. This implies that most diabetic patients will require the combination of two or more antihypertensive agents to achieve this blood pressure target. Although the most effective combination strategy in diabetes has not yet been determined in large-scale randomized clinical trials, a combination that includes at least one agent that interrupts the renin-angiotensin system appears to not only have a good safety profile, but may also provide additional renal and cardiovascular protection. Other antihypertensive agents should be added based on the patients risk profile and overall treatment regimen to achieve blood pressure goal.

摘要

高血压通常与糖尿病相关,并在增加大血管和微血管糖尿病并发症风险方面起协同作用。大规模临床试验表明,强化降压治疗可显著降低这种风险,因此,美国预防、检测、评估与治疗高血压联合委员会第七次报告指南进一步将糖尿病患者的血压目标降低至<130/80 mmHg。这意味着大多数糖尿病患者需要联合使用两种或更多种抗高血压药物才能达到这一血压目标。虽然糖尿病中最有效的联合治疗策略尚未在大规模随机临床试验中确定,但包含至少一种阻断肾素-血管紧张素系统的药物的联合治疗似乎不仅具有良好的安全性,还可能提供额外的肾脏和心血管保护。应根据患者的风险状况和整体治疗方案添加其他抗高血压药物以实现血压目标。

相似文献

1
Management strategies for patients with hypertension and diabetes: why combination therapy is critical.
J Clin Hypertens (Greenwich). 2006 Feb;8(2):108-13. doi: 10.1111/j.1524-6175.2005.04508.x.
2
Update on the management of hypertension: recent clinical trials and the JNC 7.
J Clin Hypertens (Greenwich). 2004 Oct;6(10 Suppl 2):4-13. doi: 10.1111/j.1524-6175.2004.03830.x.
5
Renal protection in hypertensive patients: selection of antihypertensive therapy.
Drugs. 2005;65 Suppl 2:29-39. doi: 10.2165/00003495-200565002-00005.
7
Update in pharmacologic treatment of hypertension.
Cardiol Clin. 2001 May;19(2):279-94, v. doi: 10.1016/s0733-8651(05)70213-7.
8
Resistant Hypertension: Which Agent?
Heart Lung Circ. 2018 Aug;27(8):911-916. doi: 10.1016/j.hlc.2018.02.013. Epub 2018 Mar 1.
9
Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.
Blood Press. 2014 Oct;23(5):262-9. doi: 10.3109/08037051.2013.876771. Epub 2014 Feb 3.
10
Treatment of hypertension in patients with diabetes: lessons from recent trials.
Cardiol Rev. 2001 Jan-Feb;9(1):36-44. doi: 10.1097/00045415-200101000-00008.

引用本文的文献

1
Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics.
Neurology. 2019 Mar 12;92(11):e1168-e1175. doi: 10.1212/WNL.0000000000007093. Epub 2019 Feb 8.
5
Initial combination therapy compared with monotherapy in diabetic hypertensive patients.
J Clin Hypertens (Greenwich). 2008 Sep;10(9):668-76. doi: 10.1111/j.1751-7176.2008.00003.x.
7
Patterns and associated health services costs of antihypertensive drug modifications.
J Clin Hypertens (Greenwich). 2008 Jan;10(1):43-50. doi: 10.1111/j.1524-6175.2007.07307.x.
8
Emerging insights in the first-step use of antihypertensive combination therapy.
J Clin Hypertens (Greenwich). 2007 Dec;9(12 Suppl 5):5-14. doi: 10.1111/j.1524-6175.2007.07807.x.

本文引用的文献

3
Preventing microalbuminuria in type 2 diabetes.
N Engl J Med. 2004 Nov 4;351(19):1941-51. doi: 10.1056/NEJMoa042167. Epub 2004 Oct 31.
5
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Hypertension. 2004 Nov;44(5):637-42. doi: 10.1161/01.HYP.0000143851.23721.26. Epub 2004 Sep 20.
9
Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
Kidney Int. 2004 Jun;65(6):1991-2002. doi: 10.1111/j.1523-1755.2004.00620.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验